According to previous evidence, both adjuvants—ISPA and Quil-A—support IL-10 production and secretion of IFN-γ, which would contribute to a balanced and regulated immune response, crucial for both effective immunity and the prevention of immune-related damage in infections like T. cruzi. This evidence concerns the gene IL10 and infection.